Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMS-025
- Development stage
- Unknown
- Lead developer
- JYAMS PET Research & Development
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
AMS-025 is a novel prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical developed for the diagnosis and potentially the treatment of prostate cancer. It is based on Sc-18F radiochemistry, utilizing a picaga chelator, which provides a single-molecule approach to construct a fluorine-18/lutetium-177 theranostic pair. The diagnostic version, [18F]AMS-025, is used as a PET imaging tracer and has demonstrated comparable diagnostic performance to [18F]PSMA-1007 in prostate cancer patients, with lower accumulation in the liver and spleen. The therapeutic counterpart, [177Lu]AMS-025, is being investigated for radioligand therapy. AMS-025 was developed by JYAMS PET Research & Development in collaboration with Chongqing DCAMS Pharmaceutical and Chongqing University Three Gorges Hospital.
- Other names
- 177Lu-AMS-02518F-AMS-025[177Lu]AMS-025[18F]AMS-025
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on AMS-025.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMS-025.